Literature DB >> 14500217

Radiofrequency ablation in the treatment of small hepatocellular carcinomas: comparison of the radiofrequency effect with and without chemoembolization.

Mikiya Kitamoto1, Masaru Imagawa, Hiroyasu Yamada, Chiyuki Watanabe, Masaaki Sumioka, Osamu Satoh, Masaru Shimamoto, Michiyo Kodama, Shojiro Kimura, Keiko Kishimoto, Yuzo Okamoto, Yasuhiko Fukuda, Kiyohiko Dohi.   

Abstract

OBJECTIVE: The purpose of this study was to determine whether a combination of transcatheter arterial chemoembolization using doxorubicin and radiofrequency ablation can increase tumor destruction compared with radiofrequency alone in the treatment for hepatocellular carcinoma. SUBJECTS AND METHODS. Twenty-one patients with 26 nodules smaller than 3 cm in diameter were treated with radiofrequency ablation. Of these, 10 nodules were treated with a combination of radiofrequency ablation and chemoembolization using doxorubicin. All nodules were evaluated for size of induced coagulation, local recurrence, and complication.
RESULTS: The therapeutic areas averaged 27.6 x 22.3 mm using an electrode with a 2-cm tip and 37.2 x 29.1 mm using an electrode with a 3-cm tip. With respect to the results for 14 nodules treated using an electrode with a 3-cm tip with or without chemoembolization, the greatest dimension of the area coagulated by combined therapy was significantly larger (longest axis dimension, 39.9 +/- 4.4 mm; shortest axis dimension, 32.3 +/- 5.2 mm; n = 7 nodules) than areas without chemoembolization (longest axis dimension, 34.6 +/- 2.6 mm; shortest axis dimension, 26.0 +/- 3.3 mm; n = 7 nodules) (longest and shortest axis dimensions, p < 0.05). No recurrence occurred in the nodules smaller than 2 cm in diameter. Among the nodules larger than 2 cm in diameter, one local recurrence was observed in seven nodules treated by combined therapy, while two local recurrences were observed in seven nodules treated by radiofrequency alone. Minor complications developed in three patients, two with persistent high fever and one with biliary stenosis.
CONCLUSION: The combination of radiofrequency ablation and transcatheter arterial chemoembolization using doxorubicin markedly increased the extent of induced coagulation compared with radiofrequency alone, despite a small number of patients and the preliminary nature of this study.

Entities:  

Mesh:

Year:  2003        PMID: 14500217     DOI: 10.2214/ajr.181.4.1810997

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


  26 in total

Review 1.  Local recurrence after hepatic radiofrequency coagulation: multivariate meta-analysis and review of contributing factors.

Authors:  Stefaan Mulier; Yicheng Ni; Jacques Jamart; Theo Ruers; Guy Marchal; Luc Michel
Journal:  Ann Surg       Date:  2005-08       Impact factor: 12.969

Review 2.  Therapeutic response assessment of RFA for HCC: contrast-enhanced US, CT and MRI.

Authors:  Yasunori Minami; Naoshi Nishida; Masatoshi Kudo
Journal:  World J Gastroenterol       Date:  2014-04-21       Impact factor: 5.742

Review 3.  Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update.

Authors:  Masao Omata; Ann-Lii Cheng; Norihiro Kokudo; Masatoshi Kudo; Jeong Min Lee; Jidong Jia; Ryosuke Tateishi; Kwang-Hyub Han; Yoghesh K Chawla; Shuichiro Shiina; Wasim Jafri; Diana Alcantara Payawal; Takamasa Ohki; Sadahisa Ogasawara; Pei-Jer Chen; Cosmas Rinaldi A Lesmana; Laurentius A Lesmana; Rino A Gani; Shuntaro Obi; A Kadir Dokmeci; Shiv Kumar Sarin
Journal:  Hepatol Int       Date:  2017-06-15       Impact factor: 6.047

4.  Non-hypervascular hypointense nodules on Gd-EOB-DTPA-enhanced MRI as a predictor of outcomes for early-stage HCC.

Authors:  Hidenori Toyoda; Takashi Kumada; Toshifumi Tada; Yasuhiro Sone; Atsuyuki Maeda; Yuji Kaneoka
Journal:  Hepatol Int       Date:  2014-07-23       Impact factor: 6.047

5.  Comparison between combination therapy of percutaneous ethanol injection and radiofrequency ablation and radiofrequency ablation alone for patients with hepatocellular carcinoma.

Authors:  Kazutaka Kurokohchi; Seishiro Watanabe; Tsutomu Masaki; Naoki Hosomi; Yoshiaki Miyauchi; Takashi Himoto; Yasuhiko Kimura; Seiji Nakai; Akihiro Deguchi; Hirohito Yoneyama; Shuhei Yoshida; Shigeki Kuriyama
Journal:  World J Gastroenterol       Date:  2005-03-14       Impact factor: 5.742

Review 6.  Combining locoregional therapies in the treatment of hepatocellular carcinoma.

Authors:  Mikhail C S S Higgins; Michael C Soulen
Journal:  Semin Intervent Radiol       Date:  2013-03       Impact factor: 1.513

Review 7.  Radiofrequency ablation of cancer.

Authors:  Marc Friedman; Igor Mikityansky; Anthony Kam; Steven K Libutti; McClellan M Walther; Ziv Neeman; Julia K Locklin; Bradford J Wood
Journal:  Cardiovasc Intervent Radiol       Date:  2004-06-03       Impact factor: 2.740

8.  Therapeutic effectiveness of echo-guided percutaneous radiofrequency ablation therapy with a LeVeen needle electrode in hepatocellular carcinoma.

Authors:  Luigi Solmi; Giovanni Nigro; Enrico Roda
Journal:  World J Gastroenterol       Date:  2006-02-21       Impact factor: 5.742

9.  Adjuvant percutaneous radiofrequency ablation of feeding artery of hepatocellular carcinoma before treatment.

Authors:  Yi-Bin Hou; Min-Hua Chen; Kun Yan; Jin-Yu Wu; Wei Yang
Journal:  World J Gastroenterol       Date:  2009-06-07       Impact factor: 5.742

10.  Regular surveillance by imaging for early detection and better prognosis of hepatocellular carcinoma in patients infected with hepatitis C virus.

Authors:  Ikue Noda; Mikiya Kitamoto; Hideki Nakahara; Ryohei Hayashi; Tomoaki Okimoto; Yoshio Monzen; Hiroyasu Yamada; Masaru Imagawa; Nobuhiko Hiraga; Junko Tanaka; Kazuaki Chayama
Journal:  J Gastroenterol       Date:  2009-10-29       Impact factor: 7.527

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.